Lupin gets FDA tentative approval for Apixaban oral suspension

Lupin gets FDA tentative approval for Apixaban oral suspension. Lupin Limited has received tentative approval from the U.S. FDA for its Apixaban Oral Suspension, 20 mg/5 mL, a generic version of Eliquis Oral Suspension. The product is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Tentative approval means the drug can be marketed upon fulfillment of certain conditions, including final FDA clearance and patent expiry.

📊 STOCKS: $LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDA